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Multipotential Progenitor Cells With a High Replating Potential 
By Catherine E. Carow, Giao Hangoc, Scott H. Cooper, Douglas E. Williams, and Hal E. Broxmeyer 
The  replating  capability  of  human multipotential (colony- 
forming  unit-granulocyte-erythrocyte-macrophage-mega- 
karyocyte [CFU-GEMM])  and erythroid (burst-forming unit- 
erythroid [BFU-E])  progenitors was assessed in vitro as a 
potential measure of self-renewal  using purified,  recombi- 
nant (r) human (hu) or murine (mu) mast cell growth factor 
(MGF),  a ligand for the c-kif  proto-oncogene receptor. Pri- 
mary cultures of human umbilical cord blood or adult human 
bone marrow cells were  initiated in methylcellulose  with 
erythropoietin (Epo) alone or in combination with rhu inter- 
leukin-3 (IL-3) or MGF. Individual day 14 to  18 CFU-GEMM  or 
BFU-E colonies  were  removed from primary  cultures and 
reseeded into  secondary methylcellulose cultures containing 
a combination  of Epo,  MGF,  and  rhu granulocyte-macro- 
phage colony-stimulating factor (GM-CSF). The data showed 
a high replating efficiency of cord blood and bone marrow 
CFU-GEMM in response to Epo  +  MGF in terms  of  the 
ATURE BLOOD CELLS are derived through the  M sequential  differentiation  of  hematopoietic  stem 
cells to progenitor  cells, which divide, in turn, to produce 
more differentiated precursor cells. Self-renewal, the poten- 
tial of a stem cell to duplicate itself, is a very important but 
poorly  understood  event  in  hematopoiesis.'  The in  vivo 
murine colony-forming unit-spleen (CFU-S) assay has been 
used to measure both stem cell self-renewal capacity and 
multipotential  stem  cell  content:'  although  the CFU-S 
assay does not appear to recognize the marrow repopulat- 
ing cell:  The in vitro counterpart of  the murine CFU-S 
assay appears to be the murine stem (S) cell assay, in which 
the  ability of  single  S-cell colonies  to be  replated  into 
secondary cultures with resultant multipotential and lineage- 
restricted  colony  formation  is  a  measure  of  S-cell self- 
renewal ~apacity.'.~  While the S cell is considered to be the 
predecessor of the colony-forming  unit-granulocyte-erythro- 
cyte-macrophage-megakaryocyte (CFU-GEMM), the exact 
relationship of  S cells to the CFU-S has yet  to be exactly 
elucidated. The S-cell assay has been modified for the study 
of human hematopoietic cell pop~lations.~~"  Murine, and to 
a lesser extent human, S cells have "self-renewal" capability 
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percentage of colonies that could be replated and the num- 
ber  of  secondary  colonies  formed  per  replated  primary 
colony. The average number of hematopoietic colonies and 
clusters  apparent from replated cultures of cord blood or 
bone marrow CFU-GEMM stimulated  by Epo + MGF was 
greater than with Epo + rhulL-3 or Epo alone. Replated cord 
blood CFU-GEMM gave rise to  CFU-GEMM, BFU-E, and GM 
colony-forming units (CFU-GM) in secondary cultures.  Re- 
plated  bone marrow CFU-GEMM gave rise mainly to  CFU-GM 
in secondary cultures. A more limited capacity for replating 
of cord blood and bone marrow BFU-E was observed. These 
studies show that CFU-GEMM responding to MGF have an 
enhanced replating potential,  which may be promoted by 
MGF. These studies also support the concept that MGF acts 
on more primitive progenitors than IL-3. 
0 1991  by The American Society of Hematology. 
based  on  colony  replating  assays,5-"  but  CFU-GEMM, 
burst-forming unit-erythroid  (BFU-E), and CFU-granulo- 
cyte-macrophage (CFU-GM) progenitors  appear to have 
little or no ability to ~eplate.'~.'~ 
The proliferation  and differentiation  of  hematopoietic 
progenitors is regulated by  a complex network of cytokines 
that  are produced  by  accessory cells  and  those  of  the 
hematopoietic  microenvironment.''  The possibility  exists 
that in early studies, culture conditions may not have been 
appropriate  for the detection of  progenitor  cell replating 
due to the lack of a specific cytokine or cytokines. Recently, 
several groups have described soluble forms of  the ligand 
for the product of  the c-kit proto-~ncogene,'~~~~  a tyrosine 
kinase re~epto?~  encoded by  the white-spotting (W) locus 
on murine chromosome 5.25,26  The ligand has been termed 
mast cell growth factor (MGF),I6-"  stem cell  and 
kit  Membrane-bound  forms  of  the 
which is  the product  of  the murine steel Iocus,'~~~'~~'  have 
also been observed. MGF is an early acting hematopoietic 
growth  factor  that  stimulates  macroscopic  BFU-E  and 
CFU-GEMM  colonies  when  used  in  combination  with 
erythropoietin  (Epo) in ~itro.'~~'~~~~-'"  Both the human and 
murine forms of MGF when used at optimal concentrations 
have equally potent costimulatory activity in the presence of 
colony-stimulating factors  for  human  bone  marrow  he- 
matopoietic progenitor cells.'" We wanted to investigate the 
effects, if  any, of  MGF on the replating potential of human 
hematopoietic progenitor cells. 
Based on assessments of  hematopoietic progenitor cells 
in single collections of  human umbilical cord and placental 
blood,  these  cell  populations  have  been  described  as 
potential sources of  stem/progenitor  cells for hematopoi- 
etic reconstitution."  Because successful hematopoietic en- 
graftment  has been  observed  in  Fanconi  and 
juvenile  chronic  myelogenous leukemia34  using  umbilical 
cord  blood  from  HLA-identical  siblings, we  wanted  to 
determine the replating capacity of  progenitor cells present 
in this cell population. The replating capabilities of  human 
umbilical cord blood CFU-GEMM and BFU-E that formed 
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colonies  in  the  presence  of  Epo  plus  purified  rhu  or 
recombinant  human  (rhu) or recombinant  murine  (rmu) 
MGF was evaluated. This capability was compared with the 
replating  potential  of  human  adult  bone  marrow  CFU- 
GEMM and BFU-E using single-colony transfer assays in 
vitro. 
MATERIALS AND METHODS 
Celh and  cell separation procedures.  Bone marrow cells were 
obtained  by  aspiration  from the posterior  iliac crest of  healthy 
volunteers  who  had  given  informed  consent  according  to  the 
guidelines established by  the Human Investigation Committee of 
the Indiana University School of  Medicine (Indianapolis). Ficolli 
Hypaque  (Pharmacia  LKB Biotechnology, Piscataway, NJ)  was 
used to separate a low-density (LD) fraction ( <  1.077 g/mL). In 
some experiments, LD cells were further separated into a nonad- 
herent LD T-lymphocyte-depleted (NALDT-) fraction by  adher- 
ence to plastic and removal of E-rosette-positiv9  cells.”  Unsepa- 
rated blood cells were obtained from umbilical cord and placental 
tissues scheduled for discard after delivery of  the infant and after 
prior need for samples for clinical study had been satisfied. The 
Human Investigation Committee of  this institution has approved 
the collection of blood in this circumstance. Umbilical cord blood 
was collected  as described  previously?’ Thawed  umbilical cord 
blood was obtained from samples that had been cryopreserved as 
described.”  LD umbilical cord blood fractions were obtained  as 
described for bone marrow. 
Cytokines.  Purified  rhu  interleukin-3  (IL-3)  and  purified 
rhuGM-CSF  each  had  specific activities  in  excess of  4  x  lo7 
CFU/mg protein  as assessed by  half-maximal tritiated thymidine 
incorporation into normal human bone marrow cell proliferation 
assays.”  The  expression  and  purification  of  rhuMGF  was  as 
described  previously for  ~~UMGF.~~.’‘  Experiments were  begun 
with rmuMGF and were continued with rhuMGF as it became 
available to us. There was no difference in the quality or quantity of 
the primary or secondary colonies or clusters that formed in the 
presence of either factor. The previously mentioned cytokines were 
obtained from Immunex Corporation (Seattle, WA). Epo (Toyobo 
New York, Inc, New York, NY) was purified from human urine. 
Colony formation by CFU-GEMM and BFU-E 
was performed as previously de~cribed.~”.”  Bone marrow cells (LD 
or NALDT-) or umbilical cord blood cells (LD or unseparated) 
were plated  at a concentration  of  either 2.5  x  lo4  or 5.0 x  lo4 
cells/mL in standard 35-mm tissue culture dishes (Corning Glass 
Works,  Coming,  NY).  Cultures  contained  a  1-mL mixture  of 
Iscove’s modified Dulbecco’s Medium (IMDM; Whittaker Bioprod- 
ucts, Inc, Walkersville, MD), 1% methylcellulose (Sigma Chemical 
Co, St Louis, MO), 30% non-heat-inactivated  fetal bovine serum 
(FBS; Hyclone Laboratories,  Inc, Logan,  UT), 5  x  lo-’  mol/L 
2-mercaptoethanol (Fisher Scientific  Co, Fair Lawn, NJ), 2 mmol/L 
glutamine (GIBCO Life Technologies,  Inc, Grand Island, NY), 
and 1 U Epo (Toyobo). In addition, cultures contained either 10% 
vol/vol IMDM, 100 U rhuIL-3,50 ng rhuMGF, or 50 ng rmuMGF. 
Cultures were incubated at 37°C in a fully humidified atmosphere 
flushed with 5%  CO, in 5% 0, for 14 to 18 days?7 CFU-GEMM 
and BFU-E colony types were assessed on whole plates using an 
inverted microscope as described pre~iously.’~~’’ 
On day 14 to 18 of  primary culture, 
single, well-isolated  CFU-GEMM or  BFU-E colonies  were  re- 
moved  from  primary  cultures  under  sterile  conditions  using  a 
micropipettor  (Gilson  P-20;  Rainin  Instrument  Co,  Emeryville, 
CA). Each colony, in a volume of primary culture not greater than 
20 )LL,  was transferred to an individual tube containing 0.64 mL of 
culture medium  and the colony was dispersed into a single-cell 
Culture system. 
Colony trunsferexperiments. 
suspension by gentle pipetting. To this, 0.56 mL of methylcellulose 
culture medium was added and the culture was mixed by vortexing. 
(The final concentration of  the components in the 1.2-mL methyl- 
cellulose culture was as described for primary cultures.) The entire 
content  of  the tube was then  plated  into  a  single 35-mm  dish 
containing 1 U/mL Epo,  100 U/mL rhuGM-CSF, and either 50 
ng/mL rhuMGF or 50 ng/mL rmuMGF using a  l-cm3 syringe. 
Secondary cultures were examined with an inverted microscope 
immediately after plating for the presence of  any cellular aggre- 
gates  that  remained.  Few  secondary  cultures  containing  such 
aggregates were noted, and these were discarded. All secondary 
cultures were incubated for 14 days as described  previously and 
scored for colonies ( >  40 cells) and clusters (5 to 40 cells) using an 
inverted microscope. 
Results are expressed as the mean f  1  SEM. Levels 
of  significance between  samples were determined  using the Stu- 
dent’s f distribution. 
Statistics. 
RESULTS 
To investigate the replating potential of human umbilical 
cord blood CFU-GEMM, a total of  861 cord blood colonies 
were  cultured  in  the presence  of  Epo alone or Epo in 
combination with rhuIL-3 or MGF (rhu or rmu)  (Table 1). 
Colonies were removed by  hand and replated individually 
into secondary cultures that contained  a combination  of 
Epo, rhuGM-CSF, and either rhuMGF or rmuMGF. The 
replating efficiency is shown as the percentage of  primary 
colonies giving rise  to at  least  one secondary colony or 
cluster. Secondary cultures contained both CFU-GM colo- 
nies (40 to > 1,000 cells) and CFU-GM clusters (5 to 40 
cells) with 46% of  growth in secondary cultures being of 
colony  size.  Erythroid  growth  on  secondary  plates  was 
mainly large BFU-E clusters ( <  40 cells). Mixed growth was 
mainly CFU-GEMM colonies, but none of these secondary 
colonies were equal in  size to the primary CFU-GEMM 
colonies from which they were derived. No correlation was 
observed between the size of replated primary colonies and 
replating efficiency. When cord blood CFU-GEMM colo- 
nies  that  had  been  initiated  in  Epo  plus  MGF  were 
transferred  to secondary cultures, an average of  46.3%  2 
5.8% of these transfers gave rise to secondary hematopoi- 
etic colonies or clusters of  multipotential (CFU-GEMM) 
and more differentiated (BFU-E and CFU-GM) lineages. 
The replating efficiency of  CFU-GEMM in response to Epo 
plus MGF was greater than that seen with CFU-GEMM 
colonies growing in primary cultures in the presence of Epo 
alone (P  < .005) or Epo plus rhuIL-3 (P  < .025). More 
importantly,  the mean  number  of  colonies plus  clusters 
present in all secondary cultures was sevenfold to ninefold 
greater when the replated CFU-GEMM colonies had been 
originally stimulated by Epo plus MGF compared to those 
grown with Epo & rhuIL-3 (P  < .01/.005). CFU-GEMM 
colonies initiated with Epo plus MGF in primary culture 
also gave rise to greater numbers of secondary multipoten- 
tial colonies plus clusters than with Epo 2 rhuIL-3 (P  < .01/ 
.05). 
Table 2 summarizes experiments with adult human bone 
marrow, in which a total of  518 randomly chosen colonies 
containing erythroid  cells (BFU-E and CFU-GEMM  not 
being distinguished) were replated into secondary cultures. 
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Table 1.  Replating Efficiency of Human Umbilical  Cord Blood Multipotential (CFU-GEMM) Hematopoietic Progenitor Cells 
Secondary Colonies and Clusters' 
Total No 
No  Primary  % Replates With  of Colonies and 
CFU-GEMM  at Least 1  CFU-GM per  BFU-E per  CFU-GEMM per  Clusters 
Primary Colonies  No.  Colonies  Colony or  Replated  Replated  Replated  per Replated 
Grown on:  Experiments  Replated  Cluster  Colonv  Colonv  Colonv  Colonv 
huEpo (1 U/mL)  10  240  27.0  2 6.3  1.6 2 0.5  0.3 f  0.1  1.5 2 0.9  3.4 2 1.2 
huEpo + rMGF (50 ng/mL)  14  333  46.3  2 5.8t~  10.2  3.1  1.2  0.9  18.0 2 rr.1~11  29.8  2 7.o~ 
huEpo + rhulL-3 (100 U/mL)  13  288  29.0 f  5.8  3.3 f  1.1  0.4 2 0.3  0.5  2 0.2  4.2  2 1.3 
These results are based on six experiments with fresh unseparated cord blood cells, two  experiments with fresh LD cord blood cells, and two 
experiments with 1-  to 3-year-old  thawed unseparated cord blood cells where the replating of CFU-GEMM  that had been grown on Epo, Epo + IL-3, 
and Epo + MGF was compared. In addition, two  experiments with 1- to 3-year-old thawed unseparated cord blood compared the replating of 
CFU-GEMM that had been cultured in Epo + IL-3 and Epo + MGF, and one experiment with 5-year-old thawed LD cord blood cells evaluated the 
replating of CFU-GEMM that were grown on Epo + MGF. The data obtained in  replating experiments in  which one or two culture conditions were 
compared was representative  of those 10 experiments in which all three culture conditions were compared. 
'Secondary  colonies were grown in the presence of huEpo (1  U/mL), rhu or rmuMGF (50 ng/mL), and rhuGM-CSF (100 U/mL). 
tCompared with mean for huEpo + rhulL-3, P < ,025. 
SCompared with mean for huEpo, P < ,005. 
§Compared  with mean for huEpo + rhulL-3, P < ,005. 
IlCompared with mean for huEpo, P < ,010. 
TCompared with mean for huEpo + rhulL-3, P < ,025. 
#Compared with mean for huEpo, P < ,050. 
Secondary  hematopoietic  colonies/clusters  formed  in 
61.8% f  5.7% of  cultures derived from erythroid colonies 
that were initiated with Epo + MGF, a replating efficiency 
that was greater than or equal to that observed with cells 
cultured with Epo alone (P  < .025) or Epo + rhuIL-3. The 
secondary  hematopoietic  colonies/clusters  that  resulted 
were mainly of  the CFU-GM lineage, although occasional 
BFU-E  developed.  When  randomly  chosen  erythroid- 
containing colonies were transferred to secondary cultures, 
rare multipotential colonies arose, and these were observed 
only in cultures of  cells replated from colonies grown with 
Epo plus MGF. The mean number of  secondary colonies 
plus clusters derived from colonies that were initiated  in 
Epo plus MGF was fourfold to sixfold greater than those 
initiated in Epo alone (P  < .005) or Epo + IL-3 (P  < .01). 
Secondary  colonies  and  clusters  derived  from  replated 
erythroid-containing  colonies were equal in  size to those 
seen  when  umbilical  cord  blood  CFU-GEMM colonies 
were transferred. 
In  selected  experiments,  adult  bone  marrow  CFU- 
GEMM were identified and were evaluated for replating 
efficiency (Table 3). When colonies grown in Epo + MGF 
were transferred  to secondary cultures, average replating 
efficiencies  varied from 52.3% to 83%. The total number of 
colonies and clusters per replated  marrow CFU-GEMM 
colony ranged from 4.5 to 28.9; for two of  the experiments 
this compared with that noted in Table 1  for replated cord 
blood CFU-GEMM (29.8 f  7.0). However, the secondary 
hematopoietic colonies  and  clusters that arose  from  re- 
plated bone marrow CFU-GEMM consisted mainly of  the 
GM type. Rare secondary multipotential colonies and only 
few secondary erythroid clusters were observed in cultures 
of  replated  bone  marrow  CFU-GEMM  colonies.  This 
finding was in contrast to the greater number of BFU-E and 
CFU-GEMM colonies formed from replated umbilical cord 
blood CFU-GEMM (Table 1). 
To compare the replating capacity of  the CFU-GEMM 
with that of  the more terminally differentiated BFU-E, we 
Table 2.  Replating Efficiency of Adult Human Bone Marrow Erythroid-Containing (CFU-GEMM plus BFU-E) Colonies 
Secondary Colonies and Clusters* 
Total No. 
No. Primary  With at Least  CFU-GM per  BFU-E per  per  Clusters 
Primary Colonies Grown on:  Experiments  Replated  Cluster  Colony  Colony  Colony  Colony 
% Replates  CFU-GEMM  of Colonies and 
No.  Colonies  1 Colony or  Replated  Replated  Replated  per Replated 
huEpo (1  U/mL)  5  192  35.0  2 5.6  1.8 t  0.8  0.1 2 0.1  0  1.9 t  0.8 
huEpo + rhulL-3 (100 U/mL)  4  132  48.0 2 8.2  2.5  t  0.4  0.2  t  0.1  0  2.7  t  0.4 
huEpo + rMGF (50 ng/mL)  5  194  61.8 2 5.7tS  9.8 2 1.7  1.0 t  0.5  0.1 t  0.1  10.8 t  1.5911 
These results are based on experiments with fresh LD (N = 2) and NALDT- (N = 3) bone marrow cells. 
'Secondary  colonies were grown in  the presence of huEpo (1  U/mL), rhu or rmuMGF (50 ng/mL), and rhuGM-CSF (100 U/mL). 
tCompared with mean for huEpo + rhulL-3, not significant (P > .05). 
SCompared with mean for huEpo, P < .025. 
§Compared  with mean for huEpo + rhulL-3, P < ,010. 
IICompared with mean for huEpo, P < ,005. 
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Table 3.  Replating Efficiency  of Adult Human Bone Marrow Multipotential (CFU-GEMM) Progenitor Cells 
Secondary Colonies and Clusters* 
Total No. 
of Colonies  % Replates  CFU-GEMM 
and Clusters 
Colonies  1 Colony or  Replated  Rep  I at  e  d  Replated  per Replated 
Primary Colonies 
Grown on huEpo (1 
UlmL) + rMGF (50 
ng/mL)  No. Primary  With at Least  CFU-GM per  BFU-E per  per 
Individual Experiments With:  Replated  Cluster  Colony  Colony  Colony  Colony 
LD cells 
NALDT- cells 
NALDT- cells 
149 
22 
18 
52.3 
82.0 
83.0 
4.4  0 
28.3  0.6 
18.4  0.7 
0.1 
0 
0 
4.5 
28.9 
19.1 
*Secondary colonies were grown in the presence of huEpo (1 U/mL), rhu or rmuMGF (50 ng/mL), and rhuGM-CSF (100  U/mL). 
replated individual umbilical cord blood  and adult bone 
marrow BFU-E colonies (Table 4). Secondary hematopoi- 
etic colonies/clusters formed on average in 46% 2 4%  of 
cultures derived from bone marrow BFU-E colonies that 
were initiated in Epo plus MGF, but the mean number of 
colonies plus clusters per replated BFU-E  was low. Second- 
ary  colonies  and  clusters  were  entirely  CFU-GM.  No 
secondary multipotential or erythroid colonies or clusters 
arose when bone marrow BFU-E were replated. Numbers 
of  secondary colonies and clusters observed when umbilical 
cord  blood  BFU-E were  replated  were  not  significantly 
different (P  > .OS)  from bone marrow BFU-E. Secondary 
growth was also mainly CFU-GM, although rare erythroid 
clusters developed in cultures from cord blood colonies that 
had been stimulated by Epo alone. 
DISCUSSION 
In previous colony replating studies, human and murine 
myeloid  progenitor  cell  “self-renewal”  was  evaluated  in 
response to a variety of  conditioned  Erythroid 
colony formation was stimulated by  the addition of  either 
Epo or  human  pla~ma.’*~’~  The results  of  these  studies 
suggested that CFU-GEMM possesses only a limited capac- 
ity for “self-renewal” based on a replating efficiency of  10% 
to  26%,  while  BFU-E  were  shown  to  have  no  “self- 
renewal”  capability.  Few  secondary  CFU-GEMM were 
detected in early studies of  colony replatings. In contrast, 
our studies have shown that in response to rhu or rmuMGF, 
human  CFU-GEMM  have  a  greater  replating  (self- 
renewal) potential than previously described. In addition, 
when umbilical cord blood CFU-GEMM were replated in 
the current study, many CFU-GEMM were observed in our 
secondary cultures that contained MGF. Human BFU-E 
appear to be capable of  limited replating,  although  to a 
lesser extent  than CFU-GEMM. The BFU-E chosen for 
replating into secondary cultures were distinguished accord- 
ing to classical colony morphology and appeared to contain 
only  hemoglobinized  cells.  While  the  limited  replating 
efficiency of BFU-E was expected, it was of  interest that the 
secondary growth was mainly of the GM type. The possibil- 
ity exists that either the BFU-E transferred into secondary 
cultures were  CFU-GEMM  with  more  limited  replating 
capacity, or that a subpopulation of BFU-E  contains a small 
but undetected population of  cells capable of nonerythroid 
differentiation. 
We have noted  in  other studies that when cultures of 
umbilical cord blood are stimulated by  optimal concentra- 
tions of  rhuGM-CSF plus rhu or rmuMGF, approximately 8 
to 10 times more CFU-GM are detectable than when cord 
blood cells are stimulated by either rhuGM-CSF or human 
urinary  bladder  carcinoma  cell line-conditioned  medium 
(5637 CM).3s  Also, when cord blood cells are grown in the 
presence of  rhuEpo, rhuIL-3, and either rhu or rmuMGF, 
approximately  13  to  14  times  more  CFU-GEMM  are 
detected  as  compared  with  when  cord  blood  cells  are 
cultured in rhuEpo and rhuIL-3. MGF also increases the 
detection of  CFU-GM, CFU-GEMM, and BFU-E in adult 
bone marrow.M  These studies suggest that the capacity of 
CFU-GEMM and BFU-E for replating in assays performed 
by  others was  underestimated  when  secondary  cultures 
contained only conditioned medium and that the presence 
of  MGF in our secondary cultures probably enhanced the 
detection  of  numbers of  secondary  colonies/clusters per 
replated colony. 
We compared the replating capabilities of  human CFU- 
GEMM and BFU-E present  in umbilical cord and adult 
Table 4.  Comparative Replating Efficiency of Adult Human Bone Marrow (EM) and Umbilical Cord Blood (CB) Erythroid (BFU-E) Progenitor Cells 
Secondary Colonies and Clusters” 
% Replates With at  Total No. of 
No. Primary  Least 1 Colony or  CFU-GEMM per  Colonies and Clusters per 
Colonies Replated  Cluster  CFU-GM per Replate  BFU-E per Replate  Replate  Replated Colony 
Grown on:  BM  CB  BM  CB  BM  CB  BM  CB  BM  CB  BM  CB 
Primary Colonies 
huEpo (1 U/mL)  40  42  24 f  6  27 f  10  0.8  f  0.1  1.4f  0.8  0  0.3 f  0.2  0  0  0.8 f  0.1  1.9 f  0.9 
huEpo (1  U/mL) + 
huMGF (50 ng/mL)  47  50  46 f  4  20 f  10  2.2 k 0.6  2.3 k 1.8  0  0  0  0  2.2 2 0.6  2.3 k 1.8 
Bone marrow  results are based on two experiments with  NALDT-  bone marrow. Cord blood results are based on three experiments with 
*Secondary colonies were grown in the presence of rhuEpo  (1 U/mL), rhuMGF (50  ng/mL), and rhuGM-CSF (100  U/mL). 
unseparated cord blood and one experiment with low-density cord blood. 
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bone  marrow.  The bone  marrow  is  the primary  site  of 
production of hematopoietic stem and progenitor cells in 
the human  adukS9  The development  of  the human  he- 
matopoietic system involves a series of organized changes in 
early embryonic and fetal development. At 3 to 4  weeks 
postconception, the yolk sac contains the first generation of 
proliferating hematopoietic stem cells. At 5 to 6 weeks, the 
yolk sac is replaced by the fetal liver as the main hematopoi- 
etic site, and later hematopoiesis takes place in the fetal 
bone marrow.39” During development, the fetal blood is 
greatly enriched in stem/progenitor cells and multipoten- 
tial  progenitor  cells  in  particular,  and  their  frequency 
equals or exceeds that of  bone marro~.~’~~~  We found no 
significant differences in the replating efficiencies, size, or 
number  of  secondary  colonies  plus  clusters  per  replate 
between cord blood and bone marrow BFU-E. It is possible 
that other cytokines may enhance the replating capability of 
BFU-E. Cord blood and bone marrow CFU-GEMM colo- 
nies were equal in size, had  essentially similar replating 
efficiencies, and the numbers and size of secondary colonies 
and clusters on replates did not differ much between bone 
marrow  and cord  blood  CFU-GEMM.  Interestingly,  the 
secondary hematopoietic colonies and clusters that were 
derived  from  replated  bone  marrow  CFU-GEMM  were 
mainly of  the more differentiated GM lineage. Rare CFU- 
GEMM were observed in cultures of replated bone marrow 
colonies.  However,  when  umbilical  cord  blood  CFU- 
GEMM replated they gave rise to large numbers of second- 
ary  CFU-GEMM.  This  difference  may  reflect  intrinsic 
differences between  cord blood  and adult marrow CFU- 
GEMM or different accessory cell populations in the two 
tissue sources. 
In summary, these  colony replating  studies show that 
cells in colonies derived from CFU-GEMM can be replated 
in  secondary  culture  and  that  CFU-GM,  BFU-E,  and 
CFU-GEMM  result.  A  strict  definition  for  self-renewal 
events would be cellular division that resulted in daughter 
cells with identical capacity for proliferation and differenti- 
ation compared with the parent  cell, although  cells with 
varying degrees of  stemness most likely exist. The data we 
report show maintenance of  differentiation along multiple 
lineages for replated  cells, which satisfies one of  the two 
criteria  for  self-renewal.  We  found  that  CFU-GEMM 
colonies formed in secondary plates were smaller than the 
CFU-GEMM  colonies in the primary plates from which 
they derived. However, it is difficult to assess the impact of 
manipulation of  cells from primary colonies before replat- 
ing and what effect this may have on the ultimate size of 
colonies  that  may  develop  in  secondary  cultures.  Also, 
colony  size is  not  necessarily an  indication  of  the self- 
renewal capacity of  the cells within the colony. Therefore, 
we at present favor the possibility that CFU-GEMM have a 
capacity  for  at  least  limited  self-renewal.  However, we 
cannot definitively rule out the possibility that the CFU- 
GEMM colonies found in  secondary plates were derived 
from  a  more  mature  CFU-GEMM  than  those  CFU- 
GEMM which  gave  rise  to colonies  in  primary  plates. 
Either explanation supports the concept that MGF is acting 
on  earlier  populations  of  progenitors.  At  present,  it  is 
difficult to discern whether the use of  MGF merely allows 
detection of  CFU-GEMM with a high replating efficiency, 
or if MGF additionally enhances the replating efficiency of 
these cells. 
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